Skip to Content
Merck
  • Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.

Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.

Journal of clinical pathology (2013-01-05)
Rosie McDonald, Abigail Tomlins, Steve Smith, Christopher Harmston
ABSTRACT

Faecal occult blood test (FOBt) is commonly requested by clinicians in both primary and secondary care. The aim of this study was to examine the use and outcomes of clinician-requested FOB testing in a single Trust taking part in the National Bowel Cancer Screening Programme pilots. Data from a single Trust was used. The Trust's pathology reporting system was searched retrospectively for all FOBt study requests in 1 year. In patients with a positive test, the Trust's clinical results reporting system was searched to determine the type and outcome of any investigations. Patients with positive tests were cross-matched with the Trust's colorectal cancer database to detect interval cancers. 1363 FOB tests were requested during the calendar year. 715 (52.5%) were completed. Mean age was 60.6 years, 30.7% of patients were in the screening age group. 60 (4.4%) patients were FOBt positive. Total colonic imaging was performed in only 22% of those who were FOBt positive. Significant pathology was detected in five patients (0.4%) including three colonic carcinomas. There were no interval cancers in the FOBt-positive group. The number of FOBt requests has increased with the introduction of a colorectal cancer screening programme. The FOBt completion rate and colonic imaging rate in FOBt-positive patients outside the national screening programme was low. Guidelines for the use of FOBt outside of screening are needed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Barium sulfate, 99.99% trace metals basis
Sigma-Aldrich
Barium sulfate, meets USP testing specifications
Sigma-Aldrich
Barium sulfate, LR, ≥98%
Sigma-Aldrich
Barium sulfate, ReagentPlus®, 99%